AGUBECIMIG
UNII 3EF7DL4G5Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Agubecimig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3EF7DL4G5Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3081156-14-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3EF7DL4G5Q

CAS Registry Number

3081156-14-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

AGUBECIMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14177

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Agubecimig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Agubecimig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Agubecimig

Common Names & Synonyms

Immunoglobulin G1 Fab fragment, bispecific, anti-(human vascular endothelial growth factor A/human interleukin-6) (synthetic human monoclonal RG6209 γ1-chain), disulfide with human monoclonal RG6209 κ-chain

agubecimig [INN]

heavy chain Fab VH humanized anti-VEGFA -G1(CH1-10h) (H) (1-223) [VH (Homo sapiens IGHV3-23*04 (76.0%) -(IGHD) -IGHJ6*01 (85.7%) T123>L (110), CDR-IMGT [7.8.9] (26-32.50-57.96-104)) (1-115) -G1(CH1-h) (Homo sapiens IGHG1*01 (100%), G1m17 (CH1 K120 (212) (116-213), hinge 1-10 (214-223)) (116-223)], (218-214')-disulfide with light chain L-kappa humanized anti-IL6 (L') (1'-214') [V-KAPPA (Homo sapiens IGKV1-5*01 (75.6%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107')) -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')], produced in Chinese hamster ovary (CHO) cells, cell line CHOK1, non-glycosylated

immunoglobulin Fab VH-G1(CH1-10h)_L-kappa, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)] and anti-[Homo sapiens IL6 (interleukin 6, IL-6), monoclonal antibody Fab humanized, bispecific, bivalent with an anti-VEGFA paratope on the VH side and an anti-IL6 paratope on the VL side

External Clinical & Regulatory Resources

Previous UNII3EF5QC8G5W

Next UNII3EFP1M282K